Cogent Biosciences Announces Proposed Public Offering of Common Stock
13 juin 2022 06h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 13, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
10 juin 2022 07h00 HE
|
Cogent Biosciences, Inc.
All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89%, regardless of prior KIT D816V inhibitor treatment All bone marrow biopsy-assessed...
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
06 juin 2022 10h15 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Annual Meeting of Stockholders
02 juin 2022 08h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
12 mai 2022 10h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., May 12, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
10 mai 2022 07h00 HE
|
Cogent Biosciences, Inc.
Initial bezuclastinib APEX data to be presented at the European Hematology Association (EHA) 2022 Annual Congress Building a portfolio of discovery stage programs, creating potential best-in-class...
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
06 mai 2022 08h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., May 06, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically...
Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event
11 avr. 2022 07h00 HE
|
Cogent Biosciences, Inc.
New bezuclastinib nonclinical data demonstrate superior selectivity against closely related kinases, as well as minimal brain penetration, compared with other KIT inhibitors ...
Cogent Biosciences to Host Virtual R&D Investor Event
29 mars 2022 07h00 HE
|
Cogent Biosciences, Inc.
CAMBRIDGE, Mass. and BOULDER, Colo., March 29, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for...
Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results
15 mars 2022 07h00 HE
|
Cogent Biosciences, Inc.
APEX, SUMMIT and PEAK bezuclastinib clinical trials actively enrolling patients APEX initial clinical data presentation expected in the first half of 2022 R&D Investor Event planned for...